<DOC>
	<DOCNO>NCT01367158</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , immunogenicity booster dose meningococcal vaccine formulation adolescent .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Third Dose One Four Different Formulations rMenB + MenACWY Combination Vaccine Adolescents Who Previously Received Same Study Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Individuals eligible enrol study male female complete study V102_02 ( primary study ) , : 1. 11 18 year time enrollment primary study ; 2. give write consent time enrollment ; 3. available visit schedule study ( ie , plan leave area end study period ) ; 4. good health determine outcome medical history , physical examination clinical judgment investigator . 1 . History meningococcal vaccine administration ; 2 . Current previous , confirm suspected disease cause N meningitidis ; 3 . Household contact and/or intimate exposure individual laboratory confirm N meningitidis infection within 60 day enrollment ; 4 . Significant acute chronic infection within previous 7 day fever ( defined temperature &gt; 38Â°C ) within previous 3 day ; 5 . Antibiotics within 7 day prior enrollment blood draw ; 6 . Pregnancy nursing ( breastfeed ) mother ; 7 . Females childbearing age use plan use acceptable birth control measure , duration study . Oral , inject implanted hormonal contraceptive , barrier method ( condom diaphragm spermicide ) ; intrauterine device sexual abstinence consider acceptable form birth control . If sexually active subject must use one accepted birth control method least two month prior study entry ; 8 . Any serious chronic progressive disease ( eg , neoplasm , diabetes , cardiac disease , hepatic disease , progressive neurological disease seizure disorder ; autoimmune disease , human immunodeficiency virus infection acquire immunodeficiency syndrome , blood dyscrasia , bleed diathesis , sign cardiac renal failure severe malnutrition ) . 9 . Known suspected impairment/alteration immune system , immunosuppressive therapy , include use corticosteroid immunosuppressive dos chronic use inhale highpotency corticosteroid immunostimulants within previous 60 day . Use topical corticosteroid administer study limited area ( ie , eczema knee face elbow ) body allow ; 10 . Receipt blood , blood product and/or plasma derivative , parenteral immunoglobulin preparation within previous 90 day ; 11 . History severe allergic reaction previous vaccination hypersensitivity vaccine component ; 12 . Individuals receive vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrollment study plan receive vaccine within 4 week study vaccine . 13 . Individuals participate clinical trial another investigational product 30 day prior first study visit intent participate another clinical study time conduct study . 14 . Individuals part study personnel close family member conduct study . 15 . Individuals medical history illness , opinion investigator , might interfere result study pose additional risk subject due participation study .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Meningococcal disease</keyword>
	<keyword>vaccine</keyword>
	<keyword>adolescent</keyword>
	<keyword>prevention</keyword>
	<keyword>Meningitis</keyword>
</DOC>